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Background: Combining different clinical agents to target multiple pathways in prostate cancer cells, including
androgen receptor (AR) signaling, is potentially an effective strategy to improve outcomes for men with metastatic
disease. We have previously demonstrated that sub-effective concentrations of an AR antagonist, bicalutamide, and
the histone deacetylase inhibitor, vorinostat, act synergistically when combined to cause death of AR-dependent
prostate cancer cells.
Methods: In this study, expression profiling of human prostate cancer cells treated with bicalutamide or vorinostat,
alone or in combination, was employed to determine the molecular mechanisms underlying this synergistic action.
Cell viability assays and quantitative real time PCR were used to validate identified candidate genes.
Results: A substantial proportion of the genes modulated by the combination of bicalutamide and vorinostat were
androgen regulated. Independent pathway analysis identified further pathways and genes, most notably NFKBIA
(encoding IκBα, an inhibitor of NF-κB and p53 signaling), as targets of this combinatorial treatment. Depletion of
IκBα by siRNA knockdown enhanced apoptosis of prostate cancer cells, while ectopic overexpression of IκBα
markedly suppressed cell death induced by the combination of bicalutamide and vorinostat.
Conclusion: These findings implicate IκBα as a key mediator of the apoptotic action of this combinatorial AR
targeting strategy and a promising new therapeutic target for prostate cancer.
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Prostate cancer is the most commonly diagnosed cancer,
and the second leading cause of cancer-related death, in
men in the developed world [1]. Since Huggins, Stevens
and Hodges [2] demonstrated that prostate epithelial
cells require androgens for growth and survival, the
mainstay of treatment for men with metastatic prostate
cancer has been suppression of testosterone production
by surgical or medical castration, a strategy termed andro-
gen deprivation therapy (ADT). Whilst these treatment* Correspondence: lisa.butler@adelaide.edu.au
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(http://creativecommons.org/publicdomain/zemodalities are initially effective (reviewed in [3]), most pa-
tients eventually relapse with castrate-resistant prostate
cancer (CRPC), which is incurable and the primary cause
of mortality associated with this disease.
It is now well established that the mediator of andro-
gen action, the androgen receptor (AR), plays a key role
in the progression of prostate cancer following ADT,
despite castrate levels of circulating testosterone. A
number of mechanisms, including increased levels of the
AR mRNA or protein [4–8], mutation of the AR gene to
produce more active or promiscuous forms of the recep-
tor [9–14], altered levels of AR coregulators (reviewed in
[15]), the expression of constitutively active AR splice
variants [16–18], and adrenal and intratumoral biosyn-
thesis of androgens [19–23], explain continued AR sig-
naling during ADT. As many of these mechanisms areis distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
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impetus to develop new and more potent agents target-
ing the androgen signaling axis. Two such agents are
enzalutamide (MDV-3100), a novel AR antagonist that
has demonstrated clinical activity in men who have
failed both ADT and docetaxel-based chemotherapy
[24], and abiraterone acetate, which targets an enzyme
required for adrenal and intratumoral androgen biosyn-
thesis. Phase III clinical trials demonstrated that these
agents extend median survival of men with advanced
CRPC by several months and both have received FDA
approval [25].
Despite the success of enzalutamide and abiraterone, it
is accepted that treatment with these agents remains es-
sentially palliative, and that combinatorial treatment
strategies targeting multiple cellular pathways in
addition to androgen signaling are more likely to im-
prove outcomes for men with CRPC. One such combin-
ation therapy comprises the AR antagonist bicalutamide
and the histone deacetylase (HDAC) inhibitor vorinostat,
which act synergistically together to cause death of cell
line models of prostate cancer [26]. Vorinostat has a glo-
bal effect on the acetylation of histones and other pro-
teins within the cell but also reduces AR levels and
activity and thereby directly targets androgen signaling
[26]. The aim of this study was to interrogate the mo-
lecular mechanisms underlying the synergistic action of
bicalutamide and vorinostat in prostate cancer. Through
expression profiling and functional studies, we identified
NFKBIA (IκBα) as a critical mediator of this therapy,
and in doing so provided novel insight into AR signaling




LNCaP human prostate cancer cells were purchased
from the American Type Culture Collection (ATCC,
Rockville, MD, USA), maintained in RPMI 1640 supple-
mented with 10 % fetal bovine serum (FBS) and used
within a range of 20–40 passages. VCaP human prostate
cancer cells were purchased from the ATCC, maintained
in DMEM supplemented with sodium pyruvate, non-
essential amino acids and 10 % FBS, and used within
60–70 passages. Vorinostat was obtained from Merck
(New Jersey, USA) and dissolved in DMSO. Bicaluta-
mide was obtained from Astra Zeneca (London, UK)
and dissolved in ethanol. Cycloheximide was obtained
from Sigma (St. Louis, MO, USA) and dissolved in
DMSO. Anti-AR (N-20), anti-prostate specific antigen
(PSA; C-19) and anti-heat shock protein 90 (HSP90; H-
114) antibodies were obtained from Santa Cruz Biotech-
nology (Santa Cruz, CA, USA). Anti-IκBα antibody was
obtained from Cell Signaling Technology Inc (Danvers,MA, USA). Anti-αtubulin antibody was obtained from
Merck Millipore (Billerica, MA, USA). Horseradish per-
oxidase conjugated anti-rabbit, anti-mouse, and anti-
sheep/goat secondary antibodies were obtained from
DAKO (Botany, NSW, Australia). Non-specific, scram-
bled siRNA and ON-TARGETplus siRNAs targeting
NFKBIA were purchased from Dharmacon (Lafayette,
CO, USA) and the NFKBIA-IRES-eGFP lentiviral ORF
plasmid was purchased from GeneCopoeia (Rockville,
MD, USA). The pLV410 eGFP lentiviral ORF plasmid
was kindly provided by Dr. Philip Gregory (University of
Adelaide, Adelaide, Australia).
Cell viability assays
LNCaP or VCaP cells were seeded in triplicate in 24-
well plates, and allowed to attach overnight before the
growth medium was replaced with medium containing
vehicle control or the indicated concentrations of vori-
nostat, bicalutamide, or the two agents in combination.
Doses were calculated based on individual dose-response
curves for each agent and cell line to ensure consistency
in the antiproliferative response between different cell
lines ([26], Additional file 1: Figure S1). Cells were
counted every 2 days using a hemocytometer and cell
viability was assessed using Trypan blue dye exclusion.
For sequential treatments, cells were treated with drug
one for 24 h, at which point the treatment medium was
removed and replaced with drug two for 48 h. To assess
the effect of cycloheximide, cells were pre-treated with
10 μM cycloheximide for 1 h, which was then removed
and replaced with treatment medium. Wash out experi-
ments were performed by allowing the treatment
medium to remain on the cells for 1, 2, 4, 6, 8, 16, or
24 h, at which point it was removed and replaced with
drug-free medium. At each end-point cells were counted
using a hemocytometer and viability assessed as above.
Microarray analysis
LNCaP cells were cultured with vehicle control, 1 μM
vorinostat, 5 μM bicalutamide, or the two agents in
combination for 6 h. Adjustment of the dose of bicaluta-
mide compared to the initial cell viability assays was ne-
cessary to ensure consistency in terms of cell death
between the two experiments, due to variation in the
sensitivity of LNCaP cells to this agent over time. Total
RNA was extracted from the cells using Trizol reagent
(Life Technologies, Carlsbad, CA, USA), and RNA integ-
rity was analyzed on an Agilent Systems Bioanalyzer.
RNA from cells treated with the combination of vorino-
stat and bicalutamide was compared with RNA from
cells treated with either vehicle control or either of the
agents individually using Affymetrix Human GeneChip
ST 1.0 arrays at the Adelaide Microarray Centre, as de-
scribed previously [27]. Differential gene expression was
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step-up multiple test correction to control the false dis-
covery rate (FDR) [28]. Adjusted p-values < 0.05 were
considered to be significant.
Quantitative real-time PCR
Independent RNA samples used to validate the micro-
array data were generated by culturing LNCaP cells with
vehicle control, 1 μM vorinostat, 2.5 μM bicalutamide or
the two agents in combination for 3, 6, 9 and 12 h. Total
RNA (1 μg) was DNAse treated with Turbo DNA Free
(Ambion, Austin, TX, USA), and then reverse tran-
scribed using an iScript cDNA Synthesis Kit (Bio-Rad,
Hercules, CA, USA). qRT-PCR was performed with a
1:10 dilution of the cDNA using SYBR green (Bio-Rad)
on a CFX Real-Time System (Bio-Rad). geNORM ana-
lysis was used to determine appropriate housekeeper
genes for each sample set. Microarray RNA was normal-
ized to HPRT1 and RPL19, and the independent sample
set was normalized to GUSB and HPRT1. Primer se-
quences are listed in Additional file 2: Table S1.
Immunoblotting
LNCaP cells cultured with 2.5 μM bicalutamide or 1 μM
vorinostat, individually and in combination, were lysed
in radioimmunoprecipitation assay lysis buffer (10 mM
Tris–HCl, 125 mM NaCl, 1 mM EDTA, 1 % Triton X-
100) supplemented with protease inhibitor cocktail
(Roche, Mannheim, Germany). Lysates (20 μg) were
electrophoresed through 7.5–15 % SDS-polyacrylamide
gels and transferred onto nitrocellulose membranes (GE
Healthcare, Buckinghamshire, UK). Membranes were
blocked overnight (4 °C) in 3 % non-fat milk powder in
Tris-buffered saline containing 0.05 % Tween-20
(TBST). Immunodetection was performed overnight at
4 °C in 3 % non-fat milk powder in TBST using an anti-
AR (1:1000) rabbit polyclonal antibody, anti-IκBα
(1:1000) mouse monoclonal antibody, or anti-PSA
(1:500) goat polyclonal antibody. Antibodies against
HSP90 (1:1000, rabbit polyclonal) and α-tubulin (1:1000,
mouse monoclonal) were used to assess loading.
Proteins were detected with horseradish peroxidase-
conjugated secondary antibodies and visualized on
autoradiography film using enhanced chemilumines-
cence detection (GE Healthcare).
Pathway analysis
Enriched gene pathways were identified using Ingenuity
Pathway Analysis (IPA), the Database for Annotation,
Visualization and Integrated Discovery (DAVID), and
Gene Set Enrichment Analysis. Significantly regulated
genes (p < 0.05) were uploaded into IPA software v9.0
(Ingenuity Systems, CA, USA) in separate lists for the
combination vs. bicalutamide alone and the combinationvs. vorinostat alone. Each gene was mapped to its corre-
sponding molecule in the Ingenuity pathways knowledge
base, and core analysis identified enriched pathways and
networks in the dataset against a background of the
Affymetrix Human GeneChip ST 1.0 array. Lists of
genes significantly regulated by the combination com-
pared to either vehicle control or either of the individual
agents were uploaded to the Functional Annotation Tool
available through DAVID (https://david.ncifcrf.gov/;
[29, 30]), converted to DAVID default IDs, and analyzed
against a background of the microarray platform. Genes
significantly regulated by the combination, either
uniquely or when compared with the individual agents,
were analyzed against a background of all genes signifi-
cantly regulated by the combination over vehicle control.
Enriched Gene Ontology (GO) biological processes and
Kyoto Encyclopedia of Genes and Genomes (KEGG)
pathways were identified using DAVID. Gene Set En-
richment Analysis [31] was implemented using the
Broad Institute’s public GenePattern server (http://gene-
pattern.broadinstitute.org/gp/pages/index.jsf ), with de-
fault parameters.
Transfection of siRNA and expression constructs
For siRNA transfection, LNCaP or VCaP cells were
seeded directly into transfection medium containing
phenol red free (PRF) RPMI 1640, lipofectamine 2000
(Life Technologies), and reconstituted scrambled siRNA
control or siRNA targeting NFKBIA at a concentration
of 10 nM. Four siRNAs were tested, and #1 and #4 were
found to be the most effective at achieving knockdown.
After 4 h of culture, additional PRF-RPMI medium con-
taining FBS and L-glutamine was added to the LNCaP
transfection mixture, while DMEM containing FBS, L-
glutamine and non-essential amino acids was added to
the VCaP transfection mixture. Cells were harvested for
counting and assessment of cell death using Trypan blue
dye exclusion, and then lysed in RIPA buffer for immu-
noblot analysis three days post-treatment (LNCaP) or six
days post-treatment (VCaP). The two timepoints used
reflect the different growth kinetics between the two cell
lines.
For transient transfection of lentiviral constructs ex-
pressing green fluorescent protein (GFP) or co-
expressing NFKBIA and GFP, LNCaP cells were seeded
at ~40 % confluency and allowed to attach overnight.
Growth medium was removed and replaced with trans-
fection medium containing PRF-RPMI, lipofectamine
2000, and 1.5 μg plasmid DNA. As for siRNA transfec-
tion, additional medium containing FBS, L-glutamine
and either vehicle control or combination therapy was
added to the transfection mix after 4 h of culture. At
three days post-treatment, fluorescent cells were visual-
ized using a fluorescent microscope, and transfection
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were then harvested and assessed for death using Trypan
blue dye exclusion, after which they were lysed in RIPA
buffer for subsequent immunoblot analysis.
Results
The combination of bicalutamide and vorinostat commits
AR-dependent prostate cancer cells to death within 8 h of
culture
Combining the AR antagonist bicalutamide with the
HDAC inhibitor vorinostat induces synergistic cell death
of prostate cancer cells, with multiple features character-
istic of apoptosis [26]. In order to accurately tailor the
design of microarray studies, the timing and cellular re-
quirements for cell death induced by the combination
were determined in AR-dependent prostate cancer cells.
A basal level of cell death of approximately 10 % in
LNCaP cells and 15–30 % in VCaP cells was observedFig. 1 Characterization of cell death caused by the combination of bicalutamid
cultured in triplicate wells with either vehicle control [VEH] bicalutamide [BIC] (
VOR], in RPMI 1640 supplemented with 10 % FBS. VCaP cells (5 × 104 cells per w
(1.25 μM) or vorinostat (0.5 μM), individually and in combination, in DMEM sup
FBS. a LNCaP cells were counted at 2, 4 and 6 days of culture with bicalutamid
b LNCaP cells were cultured with treatment one (1.) for 24 h, which was remov
pre-treated for 1 h with cycloheximide (10 μM), and then cultured for 3 d with
cells were cultured with indicated treatments, and at 1, 2, 4, 6, 8, 16, or 24 h tre
not containing either agent until a total of 72 h of culture. At each end point, c
using trypan blue dye exclusion. Cell death is expressed as a percentage of tot
are representative of three independent experiments. * = p < 0.05 using one-wwhen cells were treated with vehicle control and low
doses of bicalutamide (2.5 μM) or vorinostat (1 μM)
alone (Fig. 1a). A significant increase in cell death was
observed in LNCaP (up to 30 %) and VCaP (up to 50 %)
cells treated with the combination of bicalutamide and
vorinostat (Fig. 1a). To determine whether the synergy
was due to one agent sensitizing the cells to the other
agent, LNCaP cells were treated sequentially with each
individual agent alone and subsequently assessed for via-
bility. Maximal cell death was only achieved when both
agents were simultaneously present in culture, not when
agents were used sequentially (Fig. 1b). Pre–treatment
with the protein synthesis inhibitor cycloheximide indi-
cated that cell death induced by the combination is at
least partially reliant on de novo protein synthesis. High
dose vorinostat, known to rely on de novo protein syn-
thesis for induction of cell death [32], was included as a
positive control (Fig. 1c). Finally, drug wash out studiese and vorinostat. LNCaP cells (2 × 104 cells per well in 24-well plates) were
2.5 μM) or vorinostat [VOR] (1 μM), individually and in combination [BIC +
ell in 24-well plates) were cultured in triplicate wells with bicalutamide
plemented with sodium pyruvate, non-essential amino acids and 10 %
e and vorinostat, while VCaPs were counted at 4, 6 and 8 days of culture.
ed and replaced with treatment two (2.) for 48 h. (C) LNCaP cells were
indicated treatments (HIGH BIC = 50 μM, HIGH VOR = 7.5 μM). d LNCaP
atment medium was removed and replaced with normal culture medium
ells were counted using a haemocytometer, and assessed for viability
al cell number. Values indicated are the mean of triplicate wells ± SEM, and
ay ANOVA with Bonferroni post-hoc test
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prostate cancer cell death. A percentage of death com-
parable to a full 3 days of combination therapy (~30 %)
was observed when the cells had been cultured with the
drugs for at least 8 h or more before drug washout and
subsequent culture with standard culture media for
3 days (Fig. 1d), indicating that molecular events that in-
duce irreversible cell death occur within 6–8 h of
treatment.
Gene expression profiles in LNCaP cells treated with
bicalutamide and vorinostat
Gene expression profiling of LNCaP cells treated with
vehicle control, bicalutamide or vorinostat alone and a
combination of the agents was carried out to identify the
molecular mechanisms underlying combination-induced
cell death. A treatment time of 6 h was selected based
on the wash out study (Fig. 1d). A total of 7497 genes
were significantly modulated (p < 0.05) by the agents
alone or in combination when compared with vehicle
control (Fig. 2a). Of the 5873 genes modulated by the
combination, ~70 % were also modulated by vorinostat
alone, ~2 % were also modulated by bicalutamide alone,
and ~7 % were modulated by both of the individualFig. 2 Summary of genes expression changes after treatment with
bicalutamide, vorinostat, and the combination. LNCaP cells were
treated with vehicle control, bicalutamide, vorinostat and bicalutamide
and vorinostat in combination, and RNA was extracted at 6 h of
treatment. Microarray analysis was performed on Affymetrix Human
GeneChip 1.0 ST Arrays, with six biological replicates per sample. a Venn
diagram of genes with mRNA levels significantly changed by vorinostat
(light grey), bicalutamide (dark grey) or the doses of vorinostat and
bicalutamide in combination (white), when compared with vehicle
control. Circles represent both significantly up-regulated and significantly
down-regulated genes over vehicle control, and sizes are proportional
to the number of genes. b Numbers of genes significantly up-regulated
and significantly down-regulated by each treatment when compared
with vehicle controlagents. A total of 1209 genes (~20 %) were uniquely reg-
ulated by the combination. As expected of an HDAC in-
hibitor, which increases histone acetylation and thereby
promotes chromatin accessibility and transcriptional ac-
tivation, vorinostat induced significantly more genes
than it repressed (Fig. 2b). In contrast, bicalutamide
alone or the combination induced and repressed ap-
proximately equal proportions of genes. Three genes –
PMEPA1, PGM2L1 and STEAP1- were selected as repre-
sentative examples of the range of different expression
patterns most commonly observed, and quantified by
qRT-PCR in the microarray samples and an independ-
ently generated sample set. All three genes showed a
comparable pattern of regulation in both the microarray
and the validation RNA sets (Additional file 3: Figure
S2), indicating that the microarray data was robust.
Combined bicalutamide and vorinostat treatment
antagonizes the expression of androgen-regulated genes
As both bicalutamide and vorinostat have been shown
to modulate AR levels and activity, it was feasible that
cell death induced by the combination results from en-
hanced blockade of androgen signaling and the conse-
quent antagonism of androgen-regulated genes required
for growth and survival. To assess this possibility, genes
modulated by the combination therapy were compared
with LNCaP androgen-regulated genes defined in a pre-
vious study by Wang and colleagues [33]. Approximately
half of the androgen-regulated genes in LNCaP cells
were significantly altered by the combination treatment
(Fig. 3a). As expected, gene set enrichment analysis
(GSEA) revealed that the genes upregulated by androgen
treatment were generally repressed by the combination
treatment (Fig. 3b).
A high proportion of the genes significantly regulated by
the combination were also regulated to a similar magni-
tude by bicalutamide or vorinostat treatment alone. How-
ever, as induction of cell death was restricted to the
combination treatment, we focused on the genes that
showed selective alteration with the combination com-
pared to the individual agents. Combination treatment al-
tered 412 genes compared to vorinostat alone and 6035
genes compared to bicalutamide alone. We refined these
lists to include only the genes that were significantly al-
tered (p < 0.05; ANOVA with FDR adjustment) by the
combination when compared to both of the individual
agents, which yielded 216 genes (Fig. 3c; full list shown in
Additional file 4: Table S2). Interestingly, approximately
half of the genes in this set have been reported to be
androgen-regulated (Fig. 3d), suggesting that enhanced
blockade of androgen signaling by the combination was
likely to be a mechanism of cell death. To test this hypoth-
esis, six known androgen regulated genes, KLK2, KLK3
(PSA), NKX3-1, IGF1R, NFKBIA and C1orf116, that
Fig. 3 Changes in gene expression induced by bicalutamide and
vorinostat in prostate cancer cells are inversely related to androgen-
induced gene profiles. a Venn diagram of the overlap between
genes significantly changed by the combination of bicalutamide and
vorinostat compared with vehicle control (white) and genes significantly
changed by treatment with 100 nM DHT for 16 h from the Wang [33]
dataset (grey). Circles represent both up-regulated and down-regulated
genes and are proportional to the number of genes. b Genes regulated
by treatment with the combination of bicalutamide and vorinostat
(compared with vehicle control) are negatively correlated with
genes induced by DHT in prostate cancer cells, as assessed by
GSEA. Sextuplicate sets of expression profiles were compared
between LNCaP cells treated with vehicle control, vorinostat,
bicalutamide or the combination of vorinostat and bicalutamide.
Probe sets in the data were collapsed to gene level, assigned a
score based on a signal-to-noise ratio algorithm and rank-ordered by this
score. DHT-induced genes in the ordered data set are shown as black
lines (middle), and the running enrichment score is plotted (bottom). The
change in expression of each gene in response to the combination
treatment is shown as a heatmap (top). c Flowchart of the refinement
process involved in determining genes involved in the cell death caused
by the combination. The refined list included the 216 genes that were
significantly altered (p < 0.05; ANOVA with FDR adjustment) by
the combination when compared to both of the individual
agents. d Venn diagram of genes with mRNA levels significantly changed
by the combination of vorinostat and bicalutamide [BIC + VOR vs
individual agents] when compared with vehicle control, bicalutamide
and vorinostat individually (white) and genes regulated by 100 nM DHT
from the Wang [33] dataset (grey). Circles represent both up-regulated
and down-regulated genes and are proportional to the number of genes
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ation in the microarray compared with individual agents
alone were analyzed by qRT-PCR in an independent sam-
ple set. Each of these genes are frequently used to assess
androgen receptor signaling (32). All six genes were sig-
nificantly down regulated (>2-fold) after 6 h of treatment
with the combination when compared with vehicle con-
trol (Fig. 4a). For KLK2, KLK3 (PSA), NKX3-1, IGF1R, and
C1orf116, the effect of the combination therapy largely
paralleled that of bicalutamide treatment alone; compar-
able activity of both treatments was also observed at the
protein level for PSA (KLK3) (Fig. 4b). Interestingly,
NFKBIA, an androgen regulated gene that encodes an in-
hibitor of the NF-κB complex (IκBα), was significantly and
consistently down regulated by the combination com-
pared to individual treatments of both bicalutamide and
vorinostat at 6 h of culture. Collectively, these observa-
tions suggested that prostate cancer cell death induced by
the combination may not be occurring solely due to more
complete blockade of androgen signaling, and other path-
ways involving a subset of androgen-regulated and non-
androgen-regulated genes are likely to be involved.
Loss of NFKBIA contributes to cell death induced by the
combination of bicalutamide and vorinostat
To investigate other cellular pathways that potentially
mediate the effects of the combination therapy, three
Fig. 4 (See legend on next page.)
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Fig. 4 Quantitative analysis of androgen regulated genes altered by combinatorial AR targeting. a Quantitative real-time PCR analysis of an
independent RNA sample set, generated by treatment of LNCaP cells with vehicle control [VEH], 1 μM vorinostat [VOR], 2.5 μM bicalutamide
[BIC] or the combination of 1 μM vorinostat and 2.5 μM bicalutamide [BIC + VOR] in triplicate for 6 h. The expression of KLK2, KLK3, NKX3-1,
IGF1R, NFKBIA and C1orf116 was normalised to GUSB and HPRT1. Fold changes are expressed relative to vehicle control. Values indicated are
the mean of technical and biological replicates ± SEM, and are representative of three independent experiments. * = p < 0.05 using one-way
ANOVA with Bonferroni post-hoc test, compared with vehicle control. # = p < 0.05 using t-test compared with vorinostat, and ^ = p < 0.05
using t-test compared with bicalutamide. b Western blot analysis of lysates from LNCaP cells cultured with either vehicle control [VEH], 1 μM
vorinostat [VOR], 2.5 μM bicalutamide [BIC] or the combination of 1 μM vorinostat and 2.5 μM bicalutamide [BIC+VOR] for 12, 48, or 96 h.
Steady state levels of PSA (KLK3) are shown, and hsp90 is shown as a loading control
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utilized: Ingenuity Pathway Analysis (IPA), the Database
for Annotation, Visualization and Integrated Discovery
(DAVID), and GSEA. Due to the significant overlap be-
tween pathways enriched by the combination and the in-
dividual agents (Additional file 5: Table S3), we
restricted our analysis to the set of 216 genes (Fig. 3c)
that were significantly regulated by the combination
treatment when compared to the effects of the individualTable 1 Pathway analysis for genes significantly modulated by the c
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Inositol Phosphate Metabolism SYNJ1, SGK1, PLCB1, MAK 2.75 × 10
−6
Fo











SGK1, PLCB1, DNAJB14 2.88 × 10
−4
Pr
Glioma Signaling IGF1R 3.63 × 10
−4
Ad











GSTM2, MAF, CYP3A5 0.0013 Lo
TWEAK Signaling NFKBIA 0.0016 Ad
sig
TNFR1 Signaling NFKBIA 0.0018 Ga
TNFR2 Signaling NFKBIA 0.0023 p5
Role of CHK Proteins in Cell
Cycle Checkpoint Control
HUS1 0.0026 T c
sig
B Cell Receptor Signaling NFKBIA 0.0037 Pu
Prolactin Signaling FYN, SOCS2 0.0038 Cy
rec
PI3K/AKT Signaling NFKBIA 0.0060 He
ce
Insulin Receptor Signaling FYN, SGK1 0.0065 AB
Death Receptor Signaling NFKBIA, TNFRSF10B 0.0083 Dragent treatments. This refined gene set was enriched for
a number of pathways potentially important in the syn-
ergistic action of the combination therapy, including
pathways involved in cell cycle, cell death and cell motil-
ity, such as p53 signaling, Jak-STAT signaling, and axon
guidance (Table 1).
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therapy. Supporting this concept, the network tool in IPA
identified NFKBIA or its associated genes as central mole-
cules in the top two significantly enriched networks - Cell
Morphology, Cellular Movement and Cell Signaling, and
Cellular Movement, Drug Metabolism, Endocrine System
Development and Function (Additional file 6: Figure S3,
Additional file 7: Table S4). Furthermore, when scrutiniz-
ing the list of 216 genes with enhanced regulation by the
combination, NFKBIA was one of the most markedly
down-regulated genes in response to combination
treatment (>1.5 fold change) when compared to both
of the individual agents alone (Additional file 4: Table
S2). These results collectively implicated a role forFig. 5 The effect of combinatorial AR targeting on NFKBIA levels and p53 s
to GUSB and HPRT1. Relative expression is the fold change expressed relativ
biological replicates ± SEM, and are representative of three independent expe
test, compared with bicalutamide or vorinostat individually. b Western blot an
[VEH], 1 μM vorinostat [VOR], 2.5 μM bicalutamide [BIC] or the combination o
Steady state levels of IκBα are shown, and tubulin is shown as a loading cont
NFKBIA. * = p < 0.05 using one-way ANOVA with Bonferroni post-hoc testNFKBIA in the molecular action of the combination
treatment.
Down-regulation of NFKBIA by the combination treat-
ment was validated in a set of RNA samples generated
from an independent time-course experiment (Fig. 5a).
NFKBIA mRNA was repressed within 3 h by the com-
bination compared to both vehicle (approximately 4-
fold down-regulated) and to each agent individually
(approximately 2-fold). This repression was main-
tained for at least 6 h of culture, but returned to
levels similar to bicalutamide alone by 12 h. Western
blot analysis showed that protein levels of the corre-
sponding protein, IκBα, were also reduced by the
combination (Fig. 5b).ignaling. a The expression of NFKBIA over a timecourse was normalized
e to vehicle control. Values indicated are the mean of technical and
riments. * = p < 0.05 using one-way ANOVA with Bonferroni post-hoc
alysis of lysates from LNCaP cells cultured with either vehicle control
f 1 μM vorinostat and 2.5 μM bicalutamide [BIC+VOR] for 12, 48, or 96 h.
rol. c mRNA expression levels of TP53INP1 and CDKN1A are shown as for
Carter et al. BMC Cancer  (2016) 16:141 Page 10 of 13The significant and rapid modulation of NFKBIA sug-
gested that it might be an upstream initiator of processes
involved in cell death mediated by the combination ther-
apy. NFKBIA is a known regulator of the NF-κB and p53
signaling pathways [34], and p53 signaling was identified
as a highly enriched pathway in cells treated with the
combination (Table 1). Given this association between
NFKBIA (IκBα) and p53 signaling, the expression of two
p53 inducible genes, TP53INP1 and CDKN1A (p21) was
measured. At early time points of 3 and 6 h, neither
TP53INP1 nor CDKN1A mRNA was altered by combin-
ation therapy or either of the agents individually.
However, at 12 h of culture, the combination induced
expression of both genes by approximately four-fold
when compared with vehicle control, and two-fold
when compared with bicalutamide or vorinostat
(Fig. 5c). The up-regulation of TP53INP1 and
CDKN1A occurred after the decrease in NFKBIA, and
at a similar time point to the observed loss of IκBα
protein (Fig. 5b), supporting the hypothesis that theFig. 6 NFKBIA is a critical mediator of death induced by combinatorial AR t
cells (2 × 105 cells per well in 12-well plates) were transfected in triplicate wells
[siRNA #1 and siRNA #4] targeting NFKBIA. LNCaP cells were transfected in tripli
4 h. The transfection medium was then overlaid with vehicle control [V
of 2.5 μM bicalutamide and 1 μM vorinostat in either PRF-RPMI 1640 s
DMEM supplemented with non-essential amino acids, 1 % l-glutamine
LNCaP and VCaP cells transfected with either non-specific [N.S.] or spec
three (LNCaP) or day six (VCaP) of treatment are shown, with hsp90 as
6 days (VCaP) of treatment, and assessed for viability using trypan blue
number. Values indicated are the mean of triplicate wells ± SEM, and a
blot analysis of lysates from LNCaP cells transfected with plasmids expr
treated with vehicle control [VC] or combination [BIC+VOR]. Steady sta
as a loading control. d Cells were counted at 3 days of treatment, and
is expressed as a percentage of total cell number. Values indicated are
independent experiments. * = p < 0.05 using t-testcombination mediates NFKBIA-dependent activation
of p53 signaling.
Specific knockdown or overexpression of NFKBIA alters
LNCaP cell viability and response to the combination of
bicalutamide and vorinostat
To investigate the functional significance of NFKBIA for
prostate cancer cell viability and the observed drug re-
sponses, siRNA-mediated knockdown of NFKBIA was
performed in both LNCaP and VCaP cells. Transfection
with two different siRNAs targeting NFKBIA resulted in
a marked reduction in IκBα protein levels at 3 days
post-treatment for LNCaPs, and 6 days post-treatment
for VCaPs (Fig. 6a). Depletion of IκBα with siRNA #1 or
#4 caused a significant induction of cell death in LNCaP
cells (23–25 % compared to the basal level of 10 % ob-
served with non-specific siRNA; p < 0.05; Fig. 6b) and
VCaP cells (25 % compared to the basal level of 15 % ob-
served with non-specific siRNA; p < 0.05; Fig. 6b). This
data indicated that IκBα is an important regulator ofargeting. LNCaP cells (1 × 105 cells per well in 12-well plates) or VCaP
with 10 nM of either non-specific, scrambled siRNA [N.S.] or specific siRNAs
cate wells with 1.5 μg of plasmid expressing either GFP or NFKBIA+GFP, for
EH], or the combination [BIC + VOR] to give a final concentration
upplemented with 10 % FBS and 1 % l-glutamine (LNCaP) or
and 10 % FBS (VCaP). a Western blot analysis of lysates from
ific [#1 and #4] NFKBIA siRNA. Steady state levels of IκBα at day
a loading control. b Cells were counted at 3 days (LNCaP) or
dye exclusion. Cell death is expressed as a percentage of total cell
re representative of three independent experiments. c Western
essing GFP only [GFP] or NFKBIA and GFP [NFKBIA], and then
te levels of IκBα at day three of treatment are shown, with hsp90
assessed for viability using trypan blue dye exclusion. Cell death
the mean of triplicate wells ± SEM, and are representative of three
Carter et al. BMC Cancer  (2016) 16:141 Page 11 of 13prostate cancer cell viability in two separate AR-positive
cell lines. Moreover, IκBα depletion caused cell death of
a similar magnitude to that observed with combination
treatment, and significantly enhanced cell death caused
by the combination (Additional file 8: Figure S4).
To directly assess the importance of IκBα down-
regulation in combination therapy-mediated cell death,
we tested whether ectopic over-expression of NFKBIA
altered response to the combination treatment. Trans-
fection efficiency of the NFKBIA expression construct,
which co-expresses GFP, was estimated at between 30
and 50 % by flow cytometry and fluorescent microscopy
(data not shown). Increased levels of IκBα protein after
transfection, compared to cells transfected with a control
GFP-only expression vector, were confirmed by im-
munoblotting (Fig. 6c). Treatment of cells overexpress-
ing GFP with the combination of vorinostat and
bicalutamide induced approximately 34 % cell death
which, as expected, was significantly greater than in
vehicle-treated controls. By contrast, in cells overex-
pressing IκBα, cell death caused by the combination was
significantly reduced to ~17 %, which was not signifi-
cantly different to the basal cell death observed with ve-
hicle control treatment. This finding indicates that
downregulation of IκBα is an essential requirement for
synergistic cell death induced by the combination of
bicalutamide and vorinostat.
Discussion
Metastatic prostate cancer inevitably becomes resistant
to current hormonal therapies and, consequently, com-
binatorial therapeutic approaches that may be more effi-
cacious and less prone to resistance-associated failure
have garnered significant interest. We have previously
shown that combining the AR antagonist bicalutamide
with the HDAC inhibitor vorinostat synergistically in-
duces growth arrest and cell death in prostate cancer
cells. Importantly, this combination approach uses doses
of both agents that are individually sub-effective [26],
implying that it would minimize dose-related toxicity.
The current study provides new insight into the molecu-
lar mechanism by which these disparate agents interact
synergistically to induce death of prostate cancer cells,
and implicates IκBα, a regulator of the NF-κB and p53
pathways, as a critical factor for prostate cancer cell via-
bility and treatment response.
Given that vorinostat and bicalutamide both target
AR, we initially hypothesized that the combination of
these two agents would enhance blockade of androgen
signaling, a pathway that promotes growth and survival
of prostate cancer cells. This hypothesis was reinforced
by previous work from our laboratory demonstrating
that the combination treatment induced death only in
cells with a functional AR signaling axis, and thataddition of excess dihydrotestosterone (DHT) to the sys-
tem prevented cell death [26]. The genome-wide micro-
array expression data generated in the current study also
supported this hypothesis. Specifically, many androgen-
regulated genes were significantly altered by the combin-
ation compared to individual agents, and pathway ana-
lysis demonstrated deregulation of androgen signaling
and prostate cancer networks by the combination treat-
ment. Interestingly, for six known androgen regulated
genes, we did not observe consistently greater downreg-
ulation by the combination therapy in an independent
set of RNA samples. This could suggest that enhanced
androgen blockade is not the substantive mechanism by
which the combination exerts its effect. However, this
subset of genes only represents approximately 10 % of
the genes significantly regulated by both DHT and the
combination (when compared with the individual
agents), and 1 % of the total genes significantly regulated
by both DHT and the combination (when compared
with vehicle control). It is possible that small changes to
a large number of androgen regulated genes is an im-
portant factor in the mechanism of action of the com-
bination therapy, or that these cumulative changes are
able to sensitize the prostate cancer cells to HDAC
inhibition.
While the importance of enhanced blockade of andro-
gen signaling by the combination treatment remains am-
biguous, the expression data revealed that this treatment
also modulates a multitude of other critical cellular pro-
cesses. For example, p53 signaling and other pathways
involved in cell cycle arrest and cell death were highly
enriched in genes modulated by the combination. In con-
sidering potential mediators of the synergistic interaction
between vorinostat and bicalutamide, we noted that our
pathway analyses consistently implicated an inhibitor of
NF-κB signaling, NFKBIA, in this phenomenon. Interest-
ingly, NFKBIA is an androgen regulated gene, and the pro-
tein encoded by this gene, IκBα, is best known as an
inhibitor of NF-κB signaling. However, IκBα can also in-
hibit p53 signaling and thereby functions dichotomously
to either block p53-mediated cell death or NF-κB-
mediated cell growth [34–37], with the final phenotypic
outcome likely depending on the relative levels of NF-κB
and p53 within a given cell. At a mechanistic level, IκBα
sequesters NF-κB or p53 in the cytoplasm in an inactive
complex; following various stimulatory events, IκBα is
phosphorylated and targeted for degradation via the
ubiquitin-proteasome pathway, relieving inhibition of
these factors. With respect to prostate cancer cell death,
we observed rapid downregulation of NFKBIA in cells
treated with the combination of bicalutamide and vorino-
stat that was associated with increased expression of
TP53INP1 and CDKN1A, two commonly known p53-
inducible genes, and induction of cell death. Taken
Carter et al. BMC Cancer  (2016) 16:141 Page 12 of 13together, this data suggests that, in the context of the
combination therapy, loss of IκBα results in cell death,
which may be facilitated by the induction of p53 signaling.
This hypothesis is supported by the observation that
knockdown of NFKBIA in the absence of drug treatment
resulted in a similar level of cell death to that observed
with the combination in two independent prostate cancer
cell lines. Moreover, co-treatment with NFKBIA siRNA
and the combination therapy caused significantly more
cell death than either individual treatment. Importantly,
overexpression of NFKBIA almost completely negated the
effect of the combination treatment on cell death.
Two other observations arising from the current study
are worth noting for their clinical ramifications. First,
the combination of bicalutamide and vorinostat was effi-
cacious in models with a mutant (LNCaP) or amplified
wild-type (VCaP) AR gene. Given that many clinical
prostate cancers are characterized by aberrant AR sig-
naling, and that intra-tumoral heterogeneity may result
in foci that each potentially have structurally different
androgen receptors, this is a promising feature of the
combination therapy. Second, both vorinostat and bica-
lutamide are required simultaneously in culture for in-
duction of cell death, indicating that if sensitization is
happening it occurs rapidly. This finding indicates that
future clinical testing will require the agents to be dosed
together and not sequentially.
Conclusion
In summary, we have defined a novel mechanism of ac-
tion by which bicalutamide and vorinostat, when used in
combination, mediate death of prostate cancer cells.
While enhanced blockade of androgen signaling is po-
tentially important, we have demonstrated that other
cellular pathways also play critical roles. Specifically,
IκBα was identified as a critical regulator of therapy-
mediated cell death; this factor may have potential either
as a new therapeutic target and/or a marker of drug re-
sponse. The ability to monitor molecular markers of
apoptotic response to such therapeutic strategies will aid
in the clinical development of this combinatorial ap-
proach for treatment of prostate cancer.
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Additional file 1: Figure S1. Dose response curves of bicalutamide and
vorinostat in VCaP cells. VCaP cells (5 × 104 cells per well in 24-well plates)
were cultured in triplicate wells with bicalutamide or vorinostat at the
indicated doses in DMEM medium supplemented with sodium pyruvate,
non-essential amino acids and 10 % FBS. Cells were counted using a
haemocytometer, and assessed for viability using trypan blue dye exclusion.
Cell death is expressed as a percentage of total cell number. (PPTX 216 kb)
Additional file 2: Table S1. Primer Sequences. (DOCX 13 kb)
Additional file 3: Figure S2. Microarray validation by RT-PCR. Validation
of the microarray results, using three of the most markedly changedgenes: PMEPA1 was down-regulated by all three treatments, PGM2L1 was
up-regulated by vorinostat and the combination but not bicalutamide,
and STEAP1 was down-regulated uniquely by the combination. Expression
values taken from the microarray, qRT-PCR on three of the biological replicates
used in the microarray, and qRT-PCR on an independently generated sample
set were compared for these three genes. Three technical replicates for each
biological replicate were analysed, and the expression normalised to RPL32
and GUSB. Fold change was determined over vehicle control. Values indicated
are the mean of technical and biological replicates ± SEM. p< 0.05 using one-
way ANOVA with Tukey post-hoc test, compared with vehicle control (*),
vorinostat (#), or bicalutamide (^). (TIF 6450 kb)
Additional file 4: Table S2. List of 216 genes significantly regulated by
combination therapy versus each individual agent. (DOCX 28 kb)
Additional file 5: Table S3. Comparison of pathway analyses for
bicalutamide, vorinostat, or the combination versus vehicle control. KEGG
pathways. (DOCX 24 kb)
Additional file 6: Figure S3 Enriched networks in list of 216 genes with
enhanced regulation by the combination. The network tool in Ingenuity
Pathway Analysis (IPA) identified the networks of Cell Morphology, Cellular
Movement and Cell Signaling (A), as well as Cellular Movement, Drug
Metabolism, Endocrine System Development and Function (B), as the two
most significantly enriched by the combination treatment when compared
to the individual agents (list of 216 genes). Colors indicate the regulation by
the combination when compared to both of the individual agents – green
is downregulation, red is upregulation and half green half red means that
the combination upregulated the gene compared to one treatment, and
downregulated compared to the other. The lines in between the genes
represent a network connection. (PPTX 18374 kb)
Additional file 7: Table S4. IPA network analysis for genes regulated
by the combination when compared to individual doses of bicalutamide
and vorinostat. (DOCX 18 kb)
Additional file 8: Figure S4. Knockdown of NFKBIA enhances the cell
death effect observed with the combination therapy. (A) Western blot
analysis of lysates from LNCaP cells transfected with either non-specific
[N.S.] or specific [siRNA #1 and siRNA #4] NFKBIA siRNA and then treated
with vehicle control [VC], 2.5 μM bicalutamide [BIC], 1 μM vorinostat
[VOR], or the combination of 2.5 μM bicalutamide and 1 μM vorinostat
[BIC + VOR]. Steady state levels of IκBα at day three of treatment are
shown, with hsp90 as a loading control. (B) Cells were counted at three
days of treatment, and assessed for viability using trypan blue dye exclusion.
Cell death is expressed as a percentage of total cell number. Values indicated
are the mean of triplicate wells ± SEM, and are representative of three
independent experiments. * = p < 0.05 using t-test. (PPTX 213 kb)Abbreviations
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